Prugin is a renowned biopharmaceutical brand dedicated to developing affordable and accessible biologic drugs for the Chinese population. With a strong focus on the research and promotion of cell and gene therapy medications, Prugin has earned recognition as the Guangdong Province Cell and Gene Therapy Innovative Drug Engineering Technology Research Center. Additionally, they are a participating unit in the development of China's CAR-T drug quality standards, and some of their technologies are at the forefront of global advancements.

Prugin's product pipeline includes CAR-T, TCR-T, CAR-NK drugs, catering to various therapeutic areas such as hematologic tumors, solid tumors, and autoimmune diseases. As the leading innovative cell therapy company with multi-region global authorization for CAR-T cell drugs, Prugin adheres to a development strategy that emphasizes independent research, industrialization, and internationalization. By establishing a comprehensive cell drug development and production quality management system, Prugin has successfully built innovative and industrial core technology platforms for antibody screening, immune cell drug discovery, plasmid/viral vector process development and production, and cell drug process development and production.

They have also obtained ISO9001 quality management system certification. Prugin actively contributes to the development of national standards and legislation in the field of cell and gene therapy. They have participated in the formulation of national drug standards and the discussion of cell drug evaluation standards.

Looking ahead, Prugin aims to develop affordable biologic drugs for the Chinese population and maintain a leading position in the industry by focusing on nucleic acid, gene vector, and cell engineering industrialized technology platforms. Through continuous research, patent acquisition, and maintaining a competitive advantage, Prugin strives to become an internationally acclaimed leader in the field of innovative biopharmaceuticals